Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma

被引：0
|
作者：
Costello, Caitlin [1 ]
Ball, Edward [2 ]
Mulroney, Carolyn [2 ]
Padilla, Michelle [2 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, San Diego, CA 92103 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
Combination therapy; myeloma; relapsed/refractory multiple myeloma;
D O I：
10.1016/j.clml.2019.09.595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-311
引用
收藏
页码：E360 / E360
页数：1
相关论文
共 50 条
  • [1] Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma
    Kumar, Anupama
    Rosenberg, Aaron
    Padilla, Michelle
    Liu, Lin
    Cheng, Yuwei
    Pittman, Emily
    Tzachanis, Dimitrios
    Larson, Sarah
    Shah, Nina
    Mulroney, Carolyn
    Ball, Edward
    Costello, Caitlin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S174 - S175
  • [2] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone (DIPD) As Salvage Therapy in Early Relapsed/Refractory Multiple Myeloma
    Kumar, Anupama
    Rosenberg, Aaron S.
    Ball, Edward D.
    Larson, Sarah M.
    Sirianni, Lindsey
    Mulroney, Carolyn M.
    Costello, Caitlin L.
    BLOOD, 2023, 142
  • [3] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/ Refractory Multiple Myeloma
    Kumar, Anupama
    Rosenberg, Aaron S.
    Padilla, Michelle
    Shah, Nina
    Sirianni, Lindsey
    Liu, Lin
    Cheng, Yuwei
    Pittman, Emily
    Tzachanis, Dimitrios
    Larson, Sarah
    Mulroney, Carolyn
    Ball, Edward D.
    Costello, Caitlin
    BLOOD, 2022, 140 : 4436 - 4437
  • [4] Phase 2 Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Stage I Results
    Costello, Caitlin L.
    Brookhart, Benjamin
    Wieduwilt, Matthew J.
    Shah, Nina
    Mulroney, Carolyn
    Ball, Edward D.
    BLOOD, 2020, 136
  • [5] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Safety Run-in Analysis
    Costello, Caitlin L.
    Padilla, Michelle
    Ball, Edward D.
    Mulroney, Carolyn
    BLOOD, 2019, 134
  • [6] Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma: Stage 2 interim results.
    Kumar, Anupama Deepa
    Padilla, Michelle
    Liu, Lin
    Pu, Minya
    Pittman, Emily
    Tzachanis, Dimitrios
    Larson, Sarah Marie
    Shah, Nina
    Mulroney, Carolyn M.
    Ball, Edward David
    Rosenberg, Aaron Seth
    Costello, Caitlin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma
    Hussain, M. Junaid
    Robinson, Myra M.
    Hamadeh, Issam
    Arnall, Justin
    Bhutani, Manisha
    Atrash, Shebli
    Friend, Reed
    Pineda-Roman, Mauricio
    Symanowski, James T.
    Usmani, Saad Z.
    Voorhees, Peter M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (01) : 140 - 144
  • [8] phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Sperling, Adam
    Bianchi, Giada
    Munshi, Nikhil
    O'Donnell, Elizabeth
    Branagan, Andrew
    Avigan, David
    Liegel, Jessica
    Harrington, Cynthia
    Agyemang, Emerentia
    Lively, Kathleen
    Packer, Lisette
    Han, Samuel
    Minsky, Cole
    Riadi, Manal
    Mcvey, Cailin
    Donnelly, Kaleigh
    Smith, Caitlin
    Katzeff, Mackenna
    Goguen, Amy
    Horick, Nora
    Richardson, Paul
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S220 - S221
  • [9] A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Gasparetto, Cristina
    Bowles, Kristian M.
    Abdallah, Al-Ola
    Morris, Lura
    Mander, Gudrun
    Coppola, Sheryl
    Wang, Jing
    Ross, Jeremy A.
    Bueno, Orlando F.
    Arriola, Emma
    Mateos, Maria Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 775 - 784
  • [10] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew J.
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Bianchi, Giada
    O'Donnell, Elizabeth
    Branagan, Andrew R.
    Harrington, Cynthia C.
    Agyemang, Emerentia A.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette A.
    Bernstein, Zachary S.
    Lyons, Rebecca T.
    Riadi, Manal
    Rowell, Sean M.
    Mcvey, Cailin
    Goguen, Amy C.
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345